DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Myc Proto Oncogene Protein (Transcription Factor p64 or Class E Basic Helix Loop Helix Protein 39 or MYC) - Pipeline Review, H2 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Myc Proto Oncogene Protein, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myc Proto Oncogene Protein and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Mentioned:
- Dicerna Pharmaceuticals, Inc.
- Phylogica Limited
- Sorrento Therapeutics, Inc.
Key Topics Covered:
- Introduction
- Myc Proto Oncogene Protein Overview
- Therapeutics Development
- Pipeline Products for Myc Proto Oncogene Protein - Overview
- Pipeline Products for Myc Proto Oncogene Protein - Comparative Analysis
- Myc Proto Oncogene Protein - Therapeutics under Development by Companies
- Myc Proto Oncogene Protein - Therapeutics under Investigation by Universities/Institutes
- Myc Proto Oncogene Protein - Pipeline Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Myc Proto Oncogene Protein - Products under Development by Companies
- Myc Proto Oncogene Protein - Products under Investigation by Universities/Institutes
-
Myc Proto Oncogene Protein - Companies Involved in Therapeutics
Development
For more information about this report visit http://www.researchandmarkets.com/research/tmbjzk/myc_proto
